Cabergoline May Reduce Breast Cancer Risk
A study suggests that a medication used to suppress milk production after childbirth could significantly lower breast cancer risk.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Would you consider using a repurposed drug for breast cancer prevention if confirmed by clinical trials?
Researchers have discovered that women who use cabergoline to stop lactation following pregnancy are 70 percent less likely to develop breast cancer. The findings suggest the drug promotes necessary breast tissue involution to prevent the development of cancerous cells.
Why it matters
Incomplete breast involution after breastfeeding can leave behind cells that potentially become malignant over time. This research offers a new strategy for prevention, particularly for high-risk individuals.
A study of over 150,000 women in Spain and Norway found that cabergoline use correlates with a 70 percent reduction in breast cancer risk. Additionally, tests on mice with BRCA1 and TP53 mutations showed a 50 percent drop in tumor incidence.
The players
The Gray Foundation
This organization is a charitable entity providing the necessary funding for the upcoming multinational clinical trial of the drug.
The details
Cabergoline works by accelerating the natural process of involution, where breast tissue shrinks and cell growth is reduced after weaning. By clearing damaged cells and reducing precancerous tissue, the drug may limit the environments where tumors typically form.
Timeline
October 15, 2026: The study was published in Cancer Discovery.
The Big Picture
This research aligns with ongoing efforts within the BRCA1 genetic screening and prevention protocols to manage hereditary cancer risk. It introduces a potential pharmacological tool to complement traditional surgical or monitoring strategies for at-risk populations.
While the drug is already approved for suppressing lactation, it is not yet a standard clinical recommendation for breast cancer prevention. Patients with concerns about their cancer risk should consult with their physicians as upcoming clinical trials proceed.
The takeaway
This discovery highlights how drugs already in use for other conditions might offer untapped benefits for cancer prevention. Researchers are moving quickly to test this intervention specifically in women carrying high-risk mutations.
Further reading
Learn more about the latest developments in Cancer.
More information
View the full study published in Cancer Discovery for comprehensive clinical data.
Live Poll
Would you consider using a repurposed drug for breast cancer prevention if confirmed by clinical trials?
